Treprostinil sodium

盛夏论道，跨越山海！6月14日，夏日的热浪未能阻挡医学探索的脚步，中欧脑心联盟俱乐部第二届会议在上海火热启幕，同步召开的媒体发布会亦吸引了各界瞩目。当蝉鸣与研讨声交织，心身医学交叉领域的探索正成为这个夏天最炽热的议题——它不仅是医学研究与临床实践的关键焦点，更深刻关联着大众的身心健康与生活质量。此次会议，中外专家跨越山海相聚，带来全球心身医学前沿成果，围绕身心协同诊疗的难点与创新路径展开深度探讨。双心论坛开幕式：聚焦心身医学发展与跨学科实践突破会议在上海市精神卫生中心陈俊教授主持下展开。他提到，当前社会对精神卫生关注度不足，随着社会节奏的加快，人群抑郁症和焦虑症患病率越来越高。另一方面，不合适的报道会加重公众对精神疾病的误解与歧视，导致患者无法及时得到治疗，此次会议正是针对这些现实痛点展开研讨，强调会议内容具有重要的及时性。陈俊教授主持东南大学附属中大医院袁勇贵教授在致辞中强调中国心身医学发展历程与双心医学实践成果。他指出，自1987年启动心脏疾病与情绪关联研究以来，双心医学已形成三种诊疗模式：单纯焦虑抑郁引发心脏症状、心脏疾病伴严重精神障碍及轻症共病。通过心脏科与精神科协作，该模式实现了四大突破：提升疑难病症诊疗能力、减少医疗资源浪费、降低患者经济负担并优化医患沟通。目前全国超三分之一心脏科医生已系统掌握双心诊疗技术，推动学科向精准化方向发展。袁勇贵教授致辞意大利地中海自由大学Sabino Iliceto教授在致辞中从神经科学视角阐述脑心联动机制。他提出，大脑通过神经-内分泌-免疫网络调控全身生理功能，而心理因素如抑郁可通过介导炎症反应等机制增加心血管疾病风险。强调现代医学需突破单纯器官诊疗模式，建立“身-心-脑轴”整体观。以罗马大学研究为例，指出情绪管理对慢性病防控具有基础性作用，呼吁临床实践中将心理评估纳入常规诊疗流程，实现从“治病”到“治人”的范式转变。Sabino Iliceto教授致辞李氏大药厂董事总经理李烨妮女士致辞中回顾了企业推动国际学术交流的历程。自2015年与意大利Iliceto教授团队启动双心医学学术会议中国巡讲以来，已举办43场跨国论坛，覆盖3000余名临床医生。本次会议作为继2024年中欧脑心联盟俱乐部首次会议后的第二次专题研讨，聚焦“双心医学的前沿进展”以及“精神医学与皮肤医学的交叉领域”，旨在通过学科的交叉和融合，提升学界对治疗领域的关注，进而推动医学事业的进步。她表示，企业将持续投入创新药物研发，支持双心医学标准化诊疗路径建设，助力中国在该领域形成国际引领性成果，最终实现患者临床获益最大化。李烨妮女士致辞跨越山海·心身同治：中欧脑心联盟俱乐部2025媒体发布会纪实这场以“跨越山海·心身同治”为主题的媒体发布会，吸引了《人民日报》《国际循环》《神经时讯》《门诊》《医学界》等多家媒体到场。发布会现场，媒体记者围绕双心医学的推广策略、企业创新研发如何与临床需求结合等关键问题抛出疑问，专家们一一耐心解答，现场氛围热烈非凡。发布会现场脑心对话：从神经机制到临床实践媒体提问：作为欧洲心血管疾病与心理健康交叉学科重要研究者之一，您最初是如何关注到心身医学这一研究方向的？您对中国双心医学和心身医学的发展现状有哪些看法和建议？Sabino Iliceto教授答记者问欧洲心血管疾病与心理健康交叉学科领军人物Sabino Iliceto教授以哲思般的语言开启学术对话：“大脑不仅是身体的指挥中枢，更是身心交互的枢纽。”他指出，现代医学正经历从“器官中心”向“整体观”的范式转变。通过解析大脑防御系统的双重性——既构建身体保护机制，又可能因过度应激反应演变为致病因素，Iliceto教授揭示了心理因素在慢性病发生发展中的核心作用。这一观点在中国卫健委《全民健康行动计划》中得到政策呼应。Iliceto教授特别强调，中国双心医学发展需建立“大脑优先”的诊疗范式，将心理评估纳入临床常规流程。他描绘的未来图景中，人工智能将成为整合多组学数据、构建脑-心交互模型的革命性工具，而中国在传统医学与现代技术融合领域的独特优势，将为全球心身医学发展提供新范式。产业赋能：创新药企的战略布局媒体提问：作为始终以创新研发与患者需求为核心驱动力的制药企业，李氏大药厂如何通过具体战略布局参与并推动心身医学领域的临床实践与学术发展的？李小羿博士答记者问李氏大药厂创始人李小羿博士表示，心身医学作为现代医学的重要组成部分，其核心在于强调精神心理因素与生理因素的相互作用，对疾病预防、治疗及康复具有深远意义。李氏大药厂成立于1994年，初期聚焦心血管和感染性疾病领域，经过多年发展，在心血管领域已构建丰富产品管线，如曲前列尼尔注射液等，这些产品在临床中帮助了众多心血管疾病患者。随着对心身医学理解的深入，我们发现精神疾病对心血管疾病的影响不容忽视，例如长期精神压力、抑郁、焦虑等情绪问题可能加重心血管疾病病情，影响患者治疗效果与生活质量。李氏大药厂自2015年起，在全国范围内开展40余场中外专家巡讲、中欧脑心联盟俱乐部活动及14期Matrix Breaking News医学教育项目。通过邀请中欧心血管领域与精神医学领域知名专家，深入探讨精神因素在心血管疾病中的作用机制、临床表现及干预措施，促进了心-脑领域的经验分享与合作研究。同时，企业在精神科领域亦有布局，2021年引进盐酸曲唑酮缓释片，进一步丰富精神医学产品管线，实现心血管产品与精神科产品的协同发展，以综合治疗方式满足患者需求。李氏大药厂希望通过系列活动，推动临床医生深化对心身医学的认知，促使其在日常诊疗中更关注患者心理状态，从而为患者提供更全面、个性化的治疗方案，切实将心身医学理念落实到临床实践中。临床突破：从诊疗规范到学科建设媒体提问：在您看来，心身医学在现代医学体系中处于怎样的地位？作为中国心身医学领域的领军人物，您认为该领域在近年来取得了哪些重要进展？袁勇贵教授答记者问中国心身医学领军人物袁勇贵教授概括了学科发展：首先是科普革命，让“心身问题”进入公众认知；其次是诊疗理念革新，心身同治原则已渗透各临床科室；第三是规范体系建立，中国心身疾病分类诊断标准与国际接轨；最后是脑科学研究突破，脑-肠轴机制解析为临床现象提供科学注解。面对未来挑战，袁教授提出“三维协同”模式：学科层面需建立心身医学评估体系，社会层面要加强健康教育网络，产业层面需研发智能诊疗工具。他特别强调媒体传播的重要性：“当公众具备心理状态自我觉察能力时，很多疾病将在萌芽阶段被阻断。”跨界融合：技术驱动的医学革命媒体提问：伴随心身医学的发展进程，您认为未来行业将面临哪些核心机遇与挑战？随着科技的不断进步，如人工智能、大数据等新兴技术在心身医学领域的应用前景如何？陈俊教授答记者问Francesco Tona教授答记者问在人工智能应用前景的讨论中，Iliceto教授与陈俊教授形成学术共鸣。陈俊教授指出，心身医学是精神医学的重要组成部分，国内应提高对其重视程度。精神科医生擅长从生物-心理-社会医学模式看待疾病，强调生物、心理与社会因素的相互作用。在双心医学里，需充分关注患者的生物学变化，如免疫炎症反应与下丘脑-垂体-肾上腺轴（HPA 轴）的关联——持久应激下的高炎症反应可引发一系列身体问题，这一机制值得临床关注与研究推广。他强调，精神科医生不仅要夯实自身心身医学功底，更应推动心内科、神经内科等多学科专家形成 “大医学”思维，共同深化心身医学实践。这种跨学科思维在帕多瓦大学Francesco Tona教授的发言中得到临床印证。 Tona教授指出，心脏病学医生需明确心理问题与心血管疾病双向影响机制，具备识别心理疾病能力并与精神科医生合作，从心身整体角度评估患者，通过推广健康生活方式等形成 “心身同治” 良性循环。西方国家临床实践表明，“药物治疗+心理干预” 综合方案对心脏病患者效果显著，心身医学介入能降低疾病发作风险、提升患者生活质量，减少药物副作用，凸显心理治疗在心脏病全程管理中的关键价值。政策响应：精神卫生服务的三年行动媒体提问：2025-2027年是我国卫生健康领域重要的“儿科和精神卫生服务年”，在此背景下，李氏大药厂作为知名药企，在精神卫生领域有哪些具体行动和规划？李小羿博士指出，2025-2027年是我国卫生健康领域重要的“儿科和精神卫生服务年”，这体现了国家对精神卫生领域的高度重视，也是医药企业的责任与使命。李氏大药厂始终致力于推动精神卫生领域发展，积极响应政府“心身同治”号召，结合自身产品管线和优势，制定了明确的行动规划。今年企业的工作重点和主题为 “抑郁是一种全身性疾病的影响因素”。抑郁症不仅影响心理健康，还会对心血管、免疫、内分泌等身体多个系统产生负面影响。为此，企业今年将开展中欧脑心俱乐部会议、Matrix Breaking News 2025系列医学教育项目等，邀请肿瘤、心血管、皮肤、妇产等多领域医学专家，深入研究探讨抑郁症对不同疾病领域的影响，以提高医务人员对该影响的认知，从而为患者提供更全面的医疗服务。在产品研发方面，李氏大药厂今年计划推出洛沙平吸入剂型，该药物用于成人精神分裂症或双相Ⅰ型障碍相关激越的急性治疗，具有快速起效、使用方便等特点，能更好地满足精神疾病患者的急性治疗需求。在2025-2027年关键时期，企业将继续秉承创新和以患者为中心的理念，通过实际行动支持国家政策落地，为推动我国精神卫生事业发展贡献力量。结束语在思维碰撞中，心血管、精神医学、神经科学、罕见病、皮肤科等多学科领域的专家，共同探讨心身医学的跨学科融合路径。专家的每一个观点都闪耀着智慧的光芒，每一次探讨都为心身医学发展注入新的活力。作为连接中欧医学智慧的桥梁，本次发布会不仅呈现了全球前沿研究成果，更勾勒出未来医学模式转型的清晰图景。“跨越山海·心身同治”不仅是一个主题，更是医学发展的方向指引。它预示着，在多学科的深度融合与国际间的紧密协作下，心身医学必将迎来更广阔的发展空间，为全球患者带来更多治愈的希望与曙光。声明：本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。（来源：《国际循环》编辑部）与“李”同行招商热线020-39062882

Systemic sclerosis and myositis interstitial lung disease subtypes flagged as most difficult to manage; specialists cite lack of effective treatments and diagnostic clarity EXTON, PA, June 17, 2025 (GLOBE NEWSWIRE) -- According to Spherix Global Insights’ newly published Special Topix™: Interstitial Lung Disease in Rheumatology (US) report, both rheumatologists and pulmonologists report significant challenges in diagnosing and managing connective tissue disease-associated interstitial lung disease (CTD-ILD), with systemic sclerosis (SSc) and myositis (IIM) cited as the most difficult subtypes to treat. The research, based on responses from 138 US specialists (n=68 rheumatologists and 70 pulmonologists), highlights persistent unmet needs, diagnostic ambiguity, and a call for more robust and collaborative management strategies. The findings reflect that undiagnosed and misdiagnosed patients make up a substantial portion of the CTD-ILD population, with nearly one-third of rheumatologists and over half of pulmonologists naming differential diagnosis as a key challenge. Specialists underscore a lack of specific biomarkers, logistical biopsy issues, and overlapping symptoms as primary obstacles. “The most definitive test (biopsy) is invasive. It is difficult to find the clinicians who are willing to do it in a timely manner, and to convince the patient it needs to be done.” – Rheumatologist “Ensuring the correct diagnosis to avoid misdiagnosing the type of ILD or source of ILD. I usually employ the assistance of a rheumatologist.” – Pulmonologist “Often it would be difficult to get patients biopsied for logistical reasons, and often the pathology report would not be precise enough.” – Pulmonologist Even once diagnosed, CTD-ILD patients face a treatment landscape with few options to slow or halt disease progression. When asked about the most difficult aspects of management, specialists consistently pointed to a lack of effective and targeted therapies, with SSc-ILD and myositis-ILD receiving the highest unmet need scores. For SSc-ILD specifically, not only is it associated with the most aggressive progression and worst long-term outcomes, but it also presents a uniquely complex therapeutic challenge. The clinical burden is especially pronounced in patients with diffuse cutaneous systemic sclerosis (dcSSc), where the use of corticosteroids is often limited due to the heightened risk of scleroderma renal crisis. This leaves physicians with a narrow band of anti-fibrotic and immunosuppressive options, many of which are perceived as only modestly effective in controlling ILD progression, let alone reversing it. Even therapies with regulatory approval for SSc-ILD, such as Boehringer Ingelheim’s OFEV (nintedanib), garner only measured enthusiasm from treating physicians. While rheumatologists acknowledge nintedanib’s potential to slow functional decline, they note it does little to address the underlying autoimmune pathology. Similarly, mycophenolate mofetil and rituximab remain staples of clinical practice, yet their real-world performance is viewed as inconsistent and difficult to monitor. Across the board, satisfaction ratings for currently utilized agents fall short of expectations, reinforcing a treatment landscape still dominated by trial-and-error approaches. This disconnect between disease complexity and treatment efficacy is fueling demand for dual-acting agents, therapies that can address both systemic autoimmunity and pulmonary fibrosis. Nowhere is this demand more visible than in systemic lupus erythematosus-associated ILD (SLE-ILD), where rheumatologists express growing interest in GSK’s Benlysta (belimumab). Though not currently approved for ILD, belimumab’s immunologic mechanism and expanded label for lupus nephritis have raised hopes that similar benefit may extend to pulmonary manifestations. Across interviews and survey feedback, physicians articulate a desire for treatments that reduce systemic activity while simultaneously preventing fibrotic progression—without the need for an antifibrotic add-on with limited synergy. Looking ahead, specialists are cautiously optimistic about the pipeline. While interest in agents with antifibrotic and immunomodulatory properties is rising, physicians emphasize that what’s most needed is not just another drug, but a paradigm shift—a treatment model that reflects the multifaceted nature of CTD-ILD. As one physician summarized, the goal is to "treat the patient, not just the lungs." In addition to tracking physician sentiment and practice patterns, the study includes target product profile evaluations for several pipeline therapies: Benlysta (GSK), BMS-986278 (Bristol Myers Squibb), Nerandomilast (Boehringer Ingelheim), and Treprostinil (United Therapeutics). These profiles offer manufacturers timely insights into clinical expectations, adoption potential, and differentiation opportunities in an increasingly complex ILD treatment landscape. Special Topix ™ is an independent service that includes access to a report or series of reports based on current events or topics of interest in specialty markets covered by Spherix. About Spherix Global Insights Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle. The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community. As a trusted advisor and industry thought leader, Spherix’s unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. To learn more about Spherix Global Insights, visit spherixglobalinsights.com or connect through LinkedIn . For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here: https://clientportal.spherixglobalinsights.com NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight’s analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release. Andy Stankus, Rheumatology Franchise Head Spherix Global Insights 4848794284 andy.stankus@spherixglobalinsights.com Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.